1. Home
  2. CGBD vs EOLS Comparison

CGBD vs EOLS Comparison

Compare CGBD & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGBD
  • EOLS
  • Stock Information
  • Founded
  • CGBD 2012
  • EOLS 2012
  • Country
  • CGBD United States
  • EOLS United States
  • Employees
  • CGBD N/A
  • EOLS N/A
  • Industry
  • CGBD Finance: Consumer Services
  • EOLS Biotechnology: Pharmaceutical Preparations
  • Sector
  • CGBD Finance
  • EOLS Health Care
  • Exchange
  • CGBD Nasdaq
  • EOLS Nasdaq
  • Market Cap
  • CGBD 881.7M
  • EOLS 787.7M
  • IPO Year
  • CGBD 2017
  • EOLS 2018
  • Fundamental
  • Price
  • CGBD $18.00
  • EOLS $10.89
  • Analyst Decision
  • CGBD Hold
  • EOLS Strong Buy
  • Analyst Count
  • CGBD 4
  • EOLS 6
  • Target Price
  • CGBD $16.25
  • EOLS $22.60
  • AVG Volume (30 Days)
  • CGBD 228.5K
  • EOLS 540.7K
  • Earning Date
  • CGBD 11-05-2024
  • EOLS 11-06-2024
  • Dividend Yield
  • CGBD 2.67%
  • EOLS N/A
  • EPS Growth
  • CGBD 29.39
  • EOLS N/A
  • EPS
  • CGBD 1.72
  • EOLS N/A
  • Revenue
  • CGBD $238,921,000.00
  • EOLS $248,326,000.00
  • Revenue This Year
  • CGBD N/A
  • EOLS $33.43
  • Revenue Next Year
  • CGBD $4.63
  • EOLS $32.44
  • P/E Ratio
  • CGBD $10.44
  • EOLS N/A
  • Revenue Growth
  • CGBD 1.68
  • EOLS 34.42
  • 52 Week Low
  • CGBD $14.76
  • EOLS $9.80
  • 52 Week High
  • CGBD $18.74
  • EOLS $17.82
  • Technical
  • Relative Strength Index (RSI)
  • CGBD 65.73
  • EOLS 28.19
  • Support Level
  • CGBD $17.61
  • EOLS $10.64
  • Resistance Level
  • CGBD $18.19
  • EOLS $11.83
  • Average True Range (ATR)
  • CGBD 0.32
  • EOLS 0.49
  • MACD
  • CGBD 0.04
  • EOLS -0.07
  • Stochastic Oscillator
  • CGBD 72.03
  • EOLS 8.36

About CGBD Carlyle Secured Lending Inc.

Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Share on Social Networks: